Goldman Sachs
OMIC

Goldman Sachs’s Singular Genomics Systems, Inc. Common Stock OMIC Stock Holding History

Goldman Sachs’s Portfolio OMIC Stock Details OMIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-719
Closed -$11.1K – 6014
2024
Q1 		$11.1K Buy
719
+31
+5% +$473 ﹤0.01% 5428
2023
Q4 		$9.5K Sell
688
-1
-0.1% -$12 ﹤0.01% 5486
2023
Q3 		$7.88K Sell
689
-6,678
-91% -$124K ﹤0.01% 5416
2023
Q2 		$183K Buy
7,367
+4,932
+203% +$144K ﹤0.01% 5211
2023
Q1 		$88.4K Sell
2,435
-26,917
-92% -$1.65M ﹤0.01% 5475
2022
Q4 		$1.77M Sell
29,352
-2,029
-6% -$136K ﹤0.01% 4033
2022
Q3 		$2.35M Sell
31,381
-534
-2% -$55.8K ﹤0.01% 3840
2022
Q2 		$3.66M Sell
31,915
-4,294
-12% -$504K ﹤0.01% 3479
2022
Q1 		$6.85M Buy
36,209
+6,393
+21% +$1.48M ﹤0.01% 3045
2021
Q4 		$10.3M Buy
29,816
+1,115
+4% +$432K ﹤0.01% 2724
2021
Q3 		$9.63M Sell
28,701
-4,022
-12% -$2.06M ﹤0.01% 2767
2021
Q2 		$27M Buy
+32,723
New +$25.4M 0.01% 1792

Other funds holding OMIC

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
QM
QVIDTVM Management The Woodlands, Texas $81.4M AUM 2.94% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Goldman Sachs's OMIC Position: Q2 2024 in Review

Goldman Sachs sold out of Singular Genomics Systems, Inc. Common Stock (OMIC) in Q2 2024, closing a stake of 719 shares — an estimated $11.1K sold.

Goldman Sachs first reported a position in OMIC in Q2 2021 and held it in 12 quarters. The position peaked at $27M in Q2 2021. 24 funds tracked by Wall St. Rank hold OMIC as of Q2 2024.

  • Goldman Sachs reported no remaining Singular Genomics Systems, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Goldman Sachs sold 719 Singular Genomics Systems, Inc. Common Stock shares in Q2 2024, an estimated $11.1K.
  • Goldman Sachs first reported a position in Singular Genomics Systems, Inc. Common Stock in Q2 2021 and held it in 12 quarters.
  • Goldman Sachs's Singular Genomics Systems, Inc. Common Stock position peaked at $27M in Q2 2021.
  • 24 funds tracked by Wall St. Rank held Singular Genomics Systems, Inc. Common Stock as of Q2 2024.

Based on Goldman Sachs's 13F filing for Q2 2024, filed 13 Aug 2024.